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1. Introduction
The potential use of stem cells in advanced therapies such as tissue engineering, regenerative
medicine, cell therapy and gene therapy by virtue of their significant therapeutic potential and
clinical applications has aroused keen interest among scientists [1,2]. Cell therapy is based on
the transplantation of living cells into an organism with a view to repairing tissue or restoring
a lost or deficient function. Stem cells are the most frequently used cells for such purposes
given their ability to differentiate into other more specialized cells [3].
The chief defining feature of stem cells is their capacity for self-renewal and their ability to
differentiate into cells of various lineages. Stem cells can be classified on the basis of their
potency and their source into (i) Totipotent stem cells (zygote and 2-4 cell embryo), since these
cells are capable of giving rise to the entire organism (both embryonic and extra-embryonic
tissues); (ii) Pluripotent stem cells (embryonic stem and embryonic germ cells), which can give
rise to derivatives of all three germ layers (embryonic tissues only, but not the extra-embryonic
ones); (iii) Multipotent stem cells (adult stem cells) [4,5].
Adult stem cells are undifferentiated cells that provide a natural reservoir that is available to
replace damaged or ageing cells throughout the lifetime of the individual. They can be found
in virtually any kind of tissue including bone marrow, trabecular bone, periosteum, synovium,
muscle, adipose tissue, breast gland, gastrointestinal tract, central nervous system, lung,
peripheral blood, dermis, hair follicle, corneal limbus, etc. [6]. The clinical application of this
type of cell is associated with potentially better prospects than that of embryonic stem cells
since use of adult stem cells does not raise any ethical conflicts nor does it involve immune
rejection problems in the event of autologous implantation.
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The possibility to generate induced pluripotent stem cells (iPSCs) by reprogramming somatic
stem cells through the introduction of certain transcription factors [7-12] is radically trans‐
forming received scientific wisdom. The pluripotency of these cells, which enables them to
differentiate into cells of all three germ layers (endoderm, mesoderm, and ectoderm), makes
them an extremely valuable tool for the potential design of cell therapy protocols. iPSC
technology can indeed allow the development of patient-specific cell therapy protocols [13] as
the use of cells like iPSCs, which are genetically identical to the donor, may protect the
individual from immune rejection. Furthermore, unlike embryonic stem cells, iPSCs are not
associated with bioethical problems and are considered a "consensus" alternative that does not
require use of human oocytes or embryos and is therefore not subject to any specific regula‐
tions. Lastly, iPSCs are very similar to embryonic stem cells as far as their molecular and
functional characteristics are concerned [14-15].
Although research into iPSCs is still at an early stage, interesting results have already been
obtained in a number of monogenic and polygenic diseases of different etiologies: cardiovas‐
cular and liver diseases, immunologic, infectious, metabolic diseases, rare diseases and cancer
[16-19]. Researchers have also looked into the application of iPSCs to toxigological and
pharmacological screening for the presence of toxic and teratogenic substances [20].
Stem cell therapy is emerging as a new concept of medical application in pharmacology. For
all practical purposes, human embryonic stem cells are used in 13% of treatments, whereas
fetal stem cells are used in 2%, umbilical cord stem cells in 10%, and adult stem cells in 75% of
cases. The most significant treatment indications for gene and cell therapy have so far been
cardiovascular and ischemic diseases, diabetes, hematopoietic diseases, liver diseases and,
more recently, orthopaedics [21]. For example, over 25,000 transplants of hematopoietic stem
cells are performed every year for treatment of lymphoma, leukemia, immunodeficiency
disorders, congenital metabolic defects, hemoglobinopathies, and myelodysplastic and
myeloproliferative syndromes [22].
Each type of stem cell has its own advantages and disadvantages, which vary depending on
the different treatment protocols and the requirements of each clinical condition. Thus,
embryonic stem cells have the advantages of being pluripotent, easy to isolate and highly
productive in culture, in addition to showing a high capacity to integrate into fetal tissue during
development. By contrast, their disadvantages include immune rejection and the possibility
that they may spontaneously and uncontrollably differentiate into inadequate cell types or
even induce tumors. Adult stem cells have a high differentiation potential, are less likely to
induce an undesirable immune response and may be stimulated by drugs. Their disadvantages
include that they are scarce and difficult to harvest, grown slowly, differentiate poorly in
culture and are difficult to handle and produce in adequate amounts for transplantation. In
addition, they behave differently depending on the source tissue, show telomere shortening,
and may carry the genetic abnormalities inherited or acquired by the donor.
At least three different strategies are available for proper use of stem cells. The first one is
stimulation of endogenous stem cells by growth factors, cytokines, and second messengers,
which must be able to induce tissue self-repair. The second alternative is direct administration
of the cells so that they differentiate at the damaged or non-functional tissue sites. The third
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possibility is transplantation of cells, tissues, or organs taken from cultures of stem cell-derived
differentiated cells. The US Food and Drug Administration defines somatic cell therapy as the
administration to humans of autologous, allogeneic or xenogeneic living non-germline cells,
other than transfusion blood products, which have been manipulated, processed, propagated
or expanded ex vivo, or are drug-treated.
The most significant applications of cell therapy as a whole are expected to be related to the
treatment of organ-specific conditions such as diabetes —a typically metabolic disease—, liver
and cardiovascular conditions, immunological disorders and hereditary monogenic diseases
such as haemophilia. As one of the key advanced therapies —together with gene therapy and
tissue engineering— cell therapy will require a new legal framework that affords generalized
patient accessibility to these products and that allows governments to discharge their regula‐
tory and control duties. In this respect, the main advantage of iPSCs lies in the fact that their
use does not raise bioethical questions, which means that regulatory provisions governing
their use need not be overly stringent.
2. Induced pluripotent stem cells technology and general clinical
applications
iPSCs are obtained through the reprogramming of an individual's somatic stem cells by the
introduction of certain transcription factors. Their chief value is based on their pluripotency
to differentiate into cells of all three germ layers, which makes them an useful tool for the
discovery of new drugs and the establishment of cell therapy programs.
iPSC technology makes it possible to develop patient-specific cell therapy protocols as they
are genetically identical to the donor and thus prevent the occurrence of an immune rejection
in autologous transplantations. Moreover, unlike embryonic stem cells, they are not associated
with any ethical controversies and therefore regulatory conditions governing their use are
much less stringent.
Induced pluripotent stem cells were generated for the first time by Shinya Yamanaka's team
[8] from murine and human fibroblasts by transfecting certain transcription factors (Oct4, Sox2,
c-Myc, and Klf4) by means of retroviral vectors. (Figure 1). Thomson et al. replicated Yama‐
naka's experiments with human cells and two additional factors: Nanog and Lin28, which
rendered the reprogramming process more efficient [9].
The same group developed an alternative reprogramming method using non-integrating
episomal vectors derived from the Epstein-Barr virus (oriP/EBNA1), which may be maintained
in a stable form in transfected cells by pharmacological selection [23]. Nonetheless, it was later
reported that only two transcription factors (Oct4 and Klf4) are needed for generating the iPSCs
from neural stem cells that endogenously express high Sox2 concentrations [24].
All of these strategies require transfection through retroviral vectors and integration for in
vitro and in vivo modeling, which precludes their clinical use because of the potential risks
involved. This is the reason why several research teams have looked into the reprogramming
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of cells using plasmid vector rather than viral vector transfection [10-12]. Although reprog‐
ramming efficacy with plasmid vectors is lower ―as is also the case with non viral gene
therapy― this method significantly increases the safety of the procedure, which makes it
clinically applicable and also constitutes a source of valuable cell material that can be used for
research into reprogramming and pluripotency.
Another promising strategy consists in the direct release of reprogramming proteins through
modified versions of reprogramming factors in some of their molecular domains. These
protein-induced pluripotent stem cells (piPSCs) bind to the membrane of cells reaching their
nucleus [25]. Ding et al., have also shown that the addition of two signal transduction inhibitors
and certain cell-survival promoting chemicals (e.g. thiazovivin) can induce a 200-fold increase
in reprogramming efficacy [26].
As explained above, iPSCs technology makes it possible to establish patient-specific cell
therapy protocols [13]. On the one hand, this reduces the risk of immune rejection in autologous
transplantations by virtue of gene identity. On the other, it provides treatment that is custom‐
ized to the specific characteristics of each patient and takes into account the etiology and
severity of the condition. Moreover, induction of pluripotency has been developed for a great
variety of tissue types [9,24,27] as it is a relatively straightforward procedure and —as
mentioned above— subject to fewer regulatory constraints [28].
Important as these advantages are, there are still a few uncertainties that need to be resolved.
One of the most pressing ones is related to determining the likelihood that these iPSCs may
undergo genetic aberrations further to the reprogramming process [29].
Figure 1. Generation of human induced pluripotent stem cells for use in cell therapy, in vitro human pathology mod‐
elling and in drug discovery. Reprogramming of human somatic cells can be induced by: Viral transfection of Oct4,
Sox2, c-Myc, Klf4, Nanog and Lin28 genes; non-viral methods using a nonintegrating episomal vector derived from
Epstein-Barr virus (oriP/EBNA1), plasmid vectors or piggyBac transposon/transposase systems; direct delivery of the re‐
programming proteins (piPSCs) and signal transduction inhibitors and chemical promoters cell survival.
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In order for the clinical application of these cells to become a reality both for diagnostic
purposes and for the design of cell therapy protocols, a few methodological hurdles must still
be resolved in connection, as is often the case with pharmacological products, with their safety
profile [30]. This means basically that efforts must be directed at removing the genome in the
integrating viral vectors, eliminating the risk of tumor formation and establishing more
efficient reprogramming and differentiation protocols. Clearly our knowledge on the reprog‐
ramming mechanisms leading to pluripotency are still insufficient to understand and more
importantly control the adverse events that could potentially occur. Therefore the most
important goal for research in this field will be to study genetic modifications in animal models
by means of large-scale genome sequencing programs. This task will require sharing cell lines
with other researchers, with appropriate confidentiality protections and, eventually, patenting
scientific discoveries and developing commercial tests and therapies. It will also be necessary
to fully ascertain and confirm that pluripotency confers iPSCs with functions similar to those
of embryonic stem cells regardless of the initial source of somatic cells used [14,15].
Undoubtedly, the most attractive application of this type of strategy is the production of patient-
specific or healthy individual-specific iPSCs for replacement of damaged non-functional tissue.
Thus for example skin fibroblast-derived iPSCs have been shown to possess a high potential to
differentiate into islet-like clusters and to release insulin, which is highly relevant for diabetes
[16]. Such developments are also relevant for amyotrophic lateral sclerosis (Lou Gehrig´s disease)
[17]; adenosine deaminase deficiency-related severe combined immunodeficiency, Shwach‐
man-Bodian-Diamond syndrome, Gaucher disease type III, Duchenne and Becker muscular
dystrophy, Parkinson disease, Huntington disease, juvenile-onset, type 1 diabetes mellitus and
Down syndrome (trisomy 21)  [31];  spinal  muscular  atrophy [19];  and in  toxicology and
pharmacology for screening toxics for embryo and/or teratogenic substances [20].
The great promise of iPSCs (Figure 1) is associated to their role in the investigation of the
phyisiological mechanisms related with the biology of stem cells themselves; in the modeling
of different pathologies; and, fundamentally, in the development of therapies for human
diseases and in drug screening. In fact, since they were discovered in 2008, almost one-
hundred-and-fifty iPSCs have been established from nearly thirty fibroblast cell lines related
to over a dozen conditions, including some complex diseases such as schizophrenia and autism
and other genetic or acquired disorders such as cardiovascular or infectious diseases. Numer‐
ous types of functional cells have already been derived from iPSCs including neurons [17,32],
hematopoietic cells [33], and cardiomyocytes [34,35].
Taking into account the far-from-trivial fact that iPSCs can be obtained from individuals
affected by a disease and that they are indefinitely self-renewable and fully of human origin,
it could well be that these cells, obtained from several individuals suffering from the same
disease and presenting with similar clinical manifestations, may provide highly valuable
information about certain predisposing genes ―as in the case of diabetes mellitus― and
therefore allow physicians to provide well-grounded genetic guidance.
Human iPSCs have the potential to be used in regenerative medicine for the design of
individualized therapies and also in the field of research and development. However, it is still
necessary to optimize iPSC protocols, particularly with respect to the possible modifications
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to their genome, and to increase the efficacy of the transfection process leading to iPSC
reprogramming [36,37]. The present state of the art of reprogramming mechanisms ―viral
transfection of Oct4, Sox2, c-Myc, Klf4, Nanog and Lin28 genes; non-viral transfection using a
non-integrating episomal vector derived from the Epstein-Barr virus (oriP/EBNA1), plasmid
vectors or piggyback transposon/transposase systems; direct delivery of the reprogramming
proteins (piPSCs); and signal transduction inhibitors and chemical promoter cell survival―
will allow safe integration and the removal of ectopic transgenes, improving the efficiency of
iPSC production using a minimally invasive strategy.
3. Advanced therapies for monogenic and metabolic diseases
The progression of the different areas of biology, biotechnology and medicine leads to the
development of highly innovative new treatments and pharmacological products. In this
regard, advanced therapies based on the by-products of gene therapy, cell therapy and
nanomedicine/tissue engineering are of great importance for their potential to radically
improve treatment of a large number of conditions. The different schools of thought that
advocate the emerging concept of advanced therapies agree that the latter must be used for
the treatment of diseases (both hereditary and non-transmissible) caused by the anomalous
behavior, or complete lack of function, of a single gene (also called monogenic hereditary
diseases) or by an anomaly in several genes (polygenic diseases).
Metabolic diseases, or congenital metabolic errors, are conditions highly amenable to be
treated by the new advanced therapies as such treatments have been shown to restore
mutation-induced alterations of gene products. Proteins are the most commonly affected gene
products, although messenger RNA is also a usual victim. Alterations affect gene products,
i.e. proteins, most of which are enzymes but there is also a group of other proteins fulfilling
all kinds of different functions (structural proteins, transport proteins and signal cascade
activation proteins). Of particular interest are the proteins that participate in homeostasis and
exert their functions outside the cells that synthesize them. This is the case of coagulation
factors VIII and IX (FVIII and FIX), whose deficiency results in the development of haemophilia
A or B, respectively. Another member of this class of proteins is antitrypsin, also of hepatic
origin and secreted into the bloodstream, whose function is to prevent the digestion of
pulmonary alveoli by proteolytic enzymes. Lastly, mention should be made of proteins with
such diverse functions as transcription factors, oncogenes, tumor-suppressing genes and even
some hormones and their receptors, the latter being specifically related with diabetes mellitus,
a typically metabolic disease.
The nature of the monogenic or metabolic disease is the main factor that determines whether
a treatment that can eradicate or at least mitigate its clinical consequences is possible or not.
Before the concept of advanced therapies came to be applied to these (wide ranging) condi‐
tions, many of them were treated using both conventional/classical and more advanced
approaches.
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Advanced therapies are applied following three basic approaches: replacement of a deficient
gene by a healthy gene so that it generates a certain functional, structural or transport protein
(gene therapy); incorporation of a full array of healthy genes and proteins through perfusion
or transplantation of healthy cells (cell therapy); or tissue transplantation and formation of
healthy organs (tissue engineering). In this context, induced pluripotent stem cells can play a
very significant role and hold an enormous therapeutic potential in the fields of cell therapy
and tissue engineering.
4. Advanced therapies and induced pluripotent stem cells in the treatment
of haemophilia
Haemophilia is a recessive X-linked hereditary disorder caused by a deficiency of coagulation
factor VIII (haemophilia A) or IX (haemophilia B). The disease is considered to be severe when
factor levels are below 1% of normal values, moderate when they are between 1 and 5% and
mild when levels range between 5% and 40%. Haemophilia A is four times more common than
haemophilia B and, in terms of severity for both types, 35% of patients have the severe form,
15% the moderate form and 55% have mild haemophilia. Incidence of the disease is 1:6,000
males born alive for haemophilia A and 1:30,000 for haemophilia B [38].
The etiopathogenesis of the disease is related to different kinds of mutations (large deletions
and insertions, inversions and point mutations) that occur in the gene expressing the deficient
coagulation factor. The clinical characteristics of both types of haemophilia are very similar:
spontaneous or traumatic hemorrhages, muscle hematomas, haemophilic arthropathy
resulting from the articular damage caused by repetitive bleeding episodes in the target joints,
or hemorrhages in the central nervous system. In the absence of appropriate replacement
treatment with exogenous coagulation factors, these manifestations of the disease can have
disabling or even fatal consequences thus negatively impacting patients' quality of life and
reducing their life expectancy [39].
At present, patients with haemophilia benefit from optimized treatment schedules based on
the intravenous systemic delivery of exogenous coagulation factors, either prophylactically or
on demand. The current policy in developed countries is in general to administer a prophy‐
lactic treatment (2 or 3 times a week) from early childhood into adulthood [39]. Such prophy‐
lactic protocols result in a clear improvement in patients' quality of life on account of the
prevention of haemophilic arthropaty and other fatal manifestations of the disease as well as
a reduction in the long-term costs of treatment because of a decrease in the need of surgical
procedures such as arthrodesis, arthroplasty or synovectomy [40].
Conventional treatment of haemophilia [41,42] is currently based on the use of plasma-derived
or recombinant high-purity coagulation factor concentrates. The former are duly treated with
heat and detergent to inactivate lipid-coated viruses [43], and the latter are a recently devel‐
oped product that does not contain proteins of human or animal origin [44,45]. Both kinds of
factor boast high efficacy and safety profiles, at least for the inactivation-susceptible pathogens
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known to date. The choice of one product over the other is usually based on the clinical
characteristics of the patient and on cost and availability considerations [46,47].
Now that infections by pathogenic viruses (HIV, HCV) that were common a few decades ago
have been eradicated, the most distressing adverse effect observed when using either product
is the development of antibodies (inhibitors) against the perfused exogenous factors [48,49].
The appearance of inhibitors renders current treatment with factor concentrates inefficient,
increasing morbidity and mortality, leading to the early onset of haemophilic arthropathy and
disability and to a consequent reduction in patients' quality of life. Lastly, inhibitors result in
higher costs as treatment must be provided both for bleeding episodes and inhibitor eradica‐
tion (immune tolerance induction). The incidence of inhibitors is around 30% in haemophilia
A and 6% in haemophilia B.
The immunologic mechanism whereby these neutralizing antibodies are generated is highly
complex and involves several messenger molecules (tumor necrosis factor, interleukins…),
and cells (T-lymphocytes B-lymphocytes, macrophages...). They are directed at certain regions
in the factor molecule that interact with other components of the coagulation cascade and,
depending on their titre level and on whether they are transient or persistent, will bring about
greater or lesser alterations in the said cascade. The causes that influence inhibitor develop‐
ment may be genetic, i.e. inherent in the patients themselves [48], such as ethnicity, familial
history, type of mutation or certain changes in some of the genes involved in the immune
response; or non-genetic, i.e. environmental [50], such as age at first factor infusion, breast‐
feeding, stimulation of the immune system by other antigens or the treatment regimen used
(prophylactic vs. on demand). Whether the factor concentrate used is plasma-derived or
recombinant does not have a significant influence on the inhibitor incidence rate [51].
Short and medium-term perspectives for the treatment of haemophilia strongly rely on the
current research efforts directed at increasing the safety levels of (especially) plasma-derived
factors. Such research focuses on the detection and subsequent inactivation of emerging blood-
borne pathogens in donors such as the prions causing variant Creutzfeldt-Jakob disease, or
other potential emerging agents [52-54]. It is also important to increase the efficiency of
recombinant factors increasing their half-life (by PEGylating the factor molecule or using
fusion proteins [55-58] and attenuating their immunogenic capacity to produce inhibitors, by
chemically modifying them [59] or by developing recombinant factors of human origin [60].
In the long term, efforts must be directed at the development of advanced therapies, particu‐
larly strategies in the field of gene therapy (using of adeno-associated viral vectors) and cell
therapy (using of adult stem cells or induced pluripotent stem cells). The chief goal of these
new strategies will be to address some of the shortcomings associated with current treatment
options such as the short in vivo half-life of administered factors, the impending risk of a
pathogen-induced infection and the development of inhibitors. Another goal of the advanced
therapies (cell therapy) will be palliative treatment of the articular consequences derived from
haemophilic arthropathy [40].
Haemophilia is optimally suited for advanced therapies as it is a monogenic condition and
does not require very high expression levels of a coagulation factor to reach moderate disease
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status (Figure 2). For this reason, significant progress has been possible with respect to these
kinds of therapies: cell therapy has broken new ground with the use of several types of target
cells and gene therapy has shown particular promise with the use of viral and non-viral vectors.
In fact, haemophilia is now recognized as a condition amenable to gene therapy [61-64].
Strategies available include use of lentiviral (LVV) [65] and adeno-associated (AAV) [66]
vectors in adult stem cells and autologous fibroblasts, in platelets and in hematopoietic stem
cells; transfer by means of non-viral vectors; and repair of mutations with chimeric oligonu‐
cleotides. The studies published so far have, in the most part, not reported any severe adverse
effect resulting from the application of such strategies in the clinical trials performed.
Specifically, gene therapy trials in haemophilic patients have shown adeno-associated vectors
to represent the most promising treatment option given their excellent safety profile, even if
on occasion they may create immune response problems. Efforts are currently centered on
minimizing the incidence of immune rejection and increasing efficacy and expression time. In
this connection, several studies have been published with a view to optimizing the use of this
type of viral vectors. Among them, in a landmark study on patients with severe haemophilia
B (<1% FIX), Nathwani et al. infused their subjects with a dose of a serotype-8-pseudotyped,
self-complementary AAV vector that expresses factor IX and can efficiently transduce
hepatocytes [66]. Their results showed that factor IX expression ranged between 3 and 11% of
normal values. Significant as they may seem, these results must be considered with caution as
the expression levels achieved rather than normalize the patient's phenotype convert it to a
mild-to-moderate form. Also, concomitant treatment with glucocorticoids is needed to prevent
immune rejection and elevation of liver transaminase levels. Due account must also be taken
of the fact that the adeno-associated vector has the potential to induce hepatotoxicity. For all
these reasons, these undoubtedly encouraging results can only be considered a first step in the
development of safe and effective advanced therapies for the treatment of haemophilia.
Non-viral strategies also have a role to play in the treatment of haemophilia as they could in
the long term provide a safer alternative than viral vectors which, as we have seen, are fraught
with significant biosafety and efficacy-related problems, which have so far limited their clinical
application. Sivalingam et al. [67] evaluated the genotoxic potential of phiC31 bacteriophage
integrase-mediated transgene integration in cord-lining epithelial cells cultured from the
human umbilical cord. This non-viral strategy has made it possible to obtain stable factor VIII
secretion in vitro. Xenoimplantation of these protein-secreting cell lines into immunocompe‐
tent haemophilic mice corrects the severe form of the disease. Such implantation could prove
extremely useful as a bioimplant in the context of monogenic diseases such as haemophilia.
Our laboratory has advanced the use of nucleofection as a non-viral transfection method to
obtain factor IX expression and secretion in adult adipose tissue-derived mesenchymal stem
cells [68]. Although it is certainly true that expression efficacy with these types of protocols is
lower than when viral vectors are used, it must be underscored that these protocols do offer
much higher safety levels, with the additional advantage that increasing factor activity to
above 5% of normal values already places the patient in the mild phenotype group.
The use of cell therapy in the treatment of haemophilia has to date consisted mainly in the
transplantation of healthy cells in an attempt to repair or replace a coagulation factor defi‐
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ciency. These procedures have been conducted mainly with adult stem cells and, more
recently, with progenitor cells partially differentiated from iPSCs, albeit in most cases the
mechanisms by which transplanted cells (to a greater or lesser extent) engraft and go on to
proliferate and function remain unknown.
Aronovich  et  al.  [69],  have  shown  that  transplantation  of  embryonic  spleen  tissue
(embryonic  day  42  spleen  tissue)  in  immunocompetent  mice  with  haemophilia  A
attenuates the severity of  the disease in the 2-3 months after  the procedure.  These results
would seem to indicate  that  transplantation of  a  fetal  spleen (obtained from a develop‐
mental  stage  prior  to  the  appearance  of  T-cells)  may potentially  be  used  to  treat  some
genetic  disorders.  For  their  part,  Follenzi  et  al.  [70]  reported  that  once  liver  sinusoidal
endothelial  cells  were transplanted and successfully engrafted into mice with haemophil‐
ia  A,  they  were  seen  to  proliferate  and  partially  replace  some  areas  of  the  hepatic
endothelium.  This  resulted  in  a  restoration  of  factor  VIII  plasma  levels  and  in  the
correction  of  the  bleeding phenotype.  More  recently,  this  same team [71]  demonstrated
that  transplantation  of  bone  marrow  cells  (healthy  mouse  Kupffer  cells  ―liver  macro‐
phage/mononuclear  cells―  and  healthy  bone  marrow  derived  mesenchymal  stromal
cells)  can correct  the phenotype of  haemophilic  mice and restore factor  VIII  levels.
As  far  as  the  use  of  iPSCs  is  concerned,  the  first  paper  came from Xu et  al.  [72],  who
reported on the generation of  murine iPSCs from tail-tip fibroblasts  and their  differentia‐
tion into endothelial  cells  and their  precursors.  These iPSC-derived cells  express  specific
Figure 2. Induced pluripotent stem cells application to the treatment of haemophilia and diabetes mellitus. Autolo‐
gous transplantation of healthy differentiated cells, obtained from iPSCs, into an animal model with haemophilia or
diabetes mellitus type 1, normalizes the corresponding altered function by in vivo production of the deficient protein
or hormone.
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membrane markers  for  these cells  such as  CD31,  CD34 and Flk1,  as  well  as  factor  VIII.
Following transplantation of  these cells  into mice with haemophilia  A,  the latter  survived
the tail-clip bleeding assay by over 3 months and their  factor VIII  plasma levels  increased
to  8%-12%.  Yadav  et  al.  [73]  studied  transdifferentiation  of  iPSC-derived  endothelial
progenitor  cells  into  hepatocytes  (primary  cells  of  FVIII  synthesis).  These  transplanted
cells  were  injected  into  the  liver  parenchyma  where  they  integrated  functionally  and
made  correction  of  the  haemophilic  phenotype.  High  levels  of  FVIII  mRNA  were
detected in  the  spleen,  heart,  and kidney tissues  of  injected animals  with  no indication
of  tumor  formation  or  any  other  adverse  events  in  the  long-term.  Alipio  et  al.  [74]  for
their  part  also reported on the generation of  factor  VIII  in a  haemophilic  murine model
one year  after  transplantation of  iPSC-derived endothelial  cells.
5. Induced pluripotent stem cells in the treatment of diabetes mellitus
Diseases caused by the destruction or loss of function of a limited number of cells are good
candidates for cell therapy. Such is the case of diabetes mellitus (Figure 2).
Diabetes mellitus (DM) is classified into two broad categories: type 1 DM, which is a genetic
disease, and type 2 DM, a more generalized variety related with insulin resistance. DM,
especially the type 1 form, is associated with microvascular complications, such as retinopathy,
neuropathy or nephropathy, as well as cardiovascular problems. Type 1 DM is a T-cell
mediated autoimmune disease specifically aimed against pancreatic beta cells, which results
in insulin deficiency [75,76].
Symptoms  of  DM  include  episodes  of  lethargy  and  fatigue,  polyuria,  enuresis,  noctu‐
ria,  polydipsia,  polyphagia,  weight  loss  and abdominal  pain.  The disorder  has  a  strong
genetic  component  related  with  the  susceptibility  to  inherit  and  develop  the  disease
through  the  HLA complex  (HLA-DR and HLA-DQ genotypes)  and  other  loci  involved
in  immunologic  recognition  and  cell-to-cell  signaling  in  the  immune  system  (graft
compatibility)  [77,78].
Abnormal  T-cell  activation  in  susceptible  individuals  results  in  both  an  inflammatory
response  within  the  Langerhans  islets  and  a  humoral  immune  response  involving  the
production  of  antibodies  against  insulin-specific  beta  cell  antigens,  decarboxylase
glutamic  acid  or  the  protein  tyrosine  phosphatase  [79].  The  presence  of  one  or  more
types  of  antibodies  may  precede  the  appearance  of  type  1  diabetes  and  its  subsequent
development  [80,81].  In  any  case,  the  final  result  is  the  destruction  of  beta  cells  and
progressive  impairment  of  the  blood glucose  metabolism [82].  Some patients  with  type
1  diabetes  may  show  a  higher  susceptibility  to  other  conditions  such  as  thyroiditis,
Graves disease,  Adisson disease,  celiac disease,  myasthenia gravis  or  to degenerative skin
conditions such as  vitíligo [83-85].
The greatest incidence of type 1 DM occurs during childhood and in the early years of
adulthood with significant variations across different geographies. Diagnosis is usually made
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before the age of 20 (between 16 and 18 in 50-60% of cases) [75]. The factors involved in the
development of type 1 DM include the so-called familial predisposing factors, gestational
status, age and other iatrogenic causes.
Type 2 DM is characterized by a functional deficiency of insulin per se or by a resistance to the
hormone resulting from an alteration of the function or structure of the insulin receptor at the
level of the membrane or of any of the molecules involved in the intracytoplasmic signal
transduction cascade [86]. The metaboilic effects of insulin vary depending on the action of
the molecules that participate in signaling pathways to regulate gene expression in striated
muscle cells, adipocytes, hepatocytes and in pancreatic beta cells [87-90]. Thus, for example,
insulin resistance caused by the impairment of glucose transporter GLUT4 initially results in
a metabolic syndrome, type 2 diabetes, lipodystrophy, hypertension, polycystic ovary
syndrome or atherosclerosis.
In general, the morbidity and mortality of DM is related with the different long-term cardio‐
vascular complications associated with the disease, also taking into account other proactivat‐
ing factors such as smoking, obesity, a sedentary lifestyle, hypertension, early onset and
prolonged duration of type 1 DM, genetic predisposition and hyperglycemia.
Nephropathy, retinopathy and diabetic neuropathy are the most common microvascular
complications of DM. As regards diabetic neuropathy, this can be a focal complication
associated with diabetic amyotrophy or with cranial nerve III oculomotor palsy, or a more
generalized occurrence that can take the form of a sensorimotor polyneuropathy affecting the
autonomic nervous system, gastric motility and cardiac function. Peripheral neuropathy
together with peripheral vascular disease may lead to a diabetic foot syndrome, characterized
by ulcerations and poor healing in the lower limbs [91]. As a macrovascular complication,
cardiovascular disease accounts for 70% of mortality in individuals with type 2 DM, with the
incidence of coronary artery disease being higher in women than in men suffering from type
1 DM [92]. Atherosclerotic processes are in turn more common in patients with type 1 DM [93].
Although treatment and diagnosis of diabetes is well-established, there is a constant quest for
new drugs that may be more effective at lowering blood glucose levels, controlling their
therapeutical management —especially in younger patients—, and preserving patients' long-
term quality of life by reducing the incidence of complications resulting from the disease.
Current research is centered on unveiling the structure and function of glucose transporters,
which may offer significant therapeutic advantages [86], as well as on the development of new
fast-acting insulin analogs and more accurate subcutaneous pumps [94-98]. Commendable as
these initiatives are, it is difficult to anticipate and control factors that exert a variable influence
upon glucose levels such as nutrition, physical activity or stress. These factors alter the
glycemic environment and consequently the amount of insulin required at each point in time,
which reinforces the need to establish sophisticated artificial pumping systems that may
simulate the natural endocrine pancreas.
The continuous advancement of our understanding of the mechanisms that govern the
physiopathology of diabetes and gene susceptibility together with the multiple possibilities
currently offered by biotechnology have fuelled the researchers' interest in the development
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of all three types of advanced therapies: gene therapy, cell therapy and tissue engineering. In
this regard, although we are still at a very incipient stage [99,100], procedures based on
transplantation of insulin-secreting cells or islets obtained from stem cell differentiation may
hold valuable hope for the future.
The need to justify the human and financial investment made in the development of new
advanced therapies is as strong in diabetes as it is in haemophilia. However, in the case of the
former justification is even more compelling taking into account that an optimal and efficient
treatment is already available for the disease. The discovery of insulin as a therapeutic tool for
DM constituted an important milestone in the history of medicine even if administration of
this hormone does not fully compensate for the function lost. This is also the case with factor
replacement in haemophilia. Moreover, both coagulation factor and insulin treatment are only
palliative, never curative, which is the basic idea underlying treatment of DM and haemo‐
philia. Moreover, it is also important to take into account the potential adverse effects of these
therapies, and particularly the complications associated with DM, which derive from the fact
that it is a long-term disease.
In  addition,  advances  in  terms  of  the  clinical  transplantation  of  Langerhans  islets  have
not  met  with  the  expected  success  as  a  result  of  the  inadequate  number  of  donors
available  and  the  incidence  of  immune  rejection  of  the  newly  transplanted  beta  cells
[101].  This  has intensified efforts  aimed at  developing insulin-producing cells  from stem
cells.  iPSC technology could turn the  tide  in  this  respect  as  such cells  may be  induced
to  form  endodermal  structures,  pancreatic  and  endocrine  progenitors  and,  naturally,
differentiated insulin-producing cells  [102-104].
Built upon the knowledge gained from studies on embryonic cells about the differentiation
process, the first studies on iPSCs, whereby human cells were reprogrammed to become in
vitro differentiated insulin-producing cells, showed great promise [105,106]. However, as only
partial cell differentiation was achieved, those studies failed in their attempt to enrich insulin-
producing cell lines or assess their function.
Drawing on current knowledge on the embryonic development of the pancreas, Zhu et al. [107]
recently reported on the generation of insulin-producing pancreatic cells from iPSCs obtained
from a rhesus monkey [108]. These authors established a quantitative cytometric method to
evaluate the efficacy of cell differentiation. In addition, they increased the level of precision in
the assessment of the competence and function of the iPSCs from a rhesus monkey by means
of transplantation into immunodeficient mice. These cells were induced to form endodermal
structures, pancreatic and endocrine progenitors and insulin-producing cells. By means of a
TGF-β inhibitor, generation of endocrine precursor cells capable of generating insulin-
producing cells that respond to glucose stimulation in vitro was undertaken. Transplantation
of these cells into a type 1 DM murine model decreased blood glucose levels in 50% of the mice.
These results show the high efficacy that can be achieved by obtaining iPSCs from a superior
animal model as well as the capacity of iPSCs to be transformed into insulin-producing cells,
which opens up the possibility for carrying out autologous transplantations in the future.
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Along the same lines, Jeon et al. [109] studied the functionality of iPSC-derived insulin-
producing cells generated from pancreas-derived epithelial cells in non-obese diabetic mice.
The insulin-producing cells obtained in this way express different pancreatic β cell markers
and secrete insulin in response to glucose stimulation. Transplantation of these cells into non-
obese diabetic mice (a model of autoimmune type 1 DM very similar to the human form) results
in a kidney graft with a functional response to glucose stimulation and a consequent normal‐
ization of blood glucose levels (Figure 2).
Until recently, iPSC generation from patients with type 2 DM had not been reported in the
literature. However, Ohmine et al. [110] described not long ago the generation of iPSCs from
keratinocytes of elderly patients with type 2 DM. These cells were reprogrammed by lentiviral
transduction with human transcription factors OCT4, SOX2, KLF4 and cMYC, telomere
elongation, and down-regulation of senescence and apoptosis-related genes, and were
subsequently differentiated into insulin-producing islet-like cells. Reprogramming of kerati‐
nocytes from elderly type 2 DM patients produces efficient iPSCs with a "privileged" senes‐
cence status that allows them to transform into insulin-producing islet-like cells, which may
lead to the development of a versatile strategy for modeling the disease as well as an advanced
therapy for treating it.
Generally speaking, several problems must yet be resolved before iPSCs can be applied
clinically, specifically to the treatment of haemophilia or diabetes. In the first place, it is
essential to optimize the reprogramming process so that it provides maximum safety assur‐
ances against the potential risks derived from undesirable genetic changes in iPSCs [111].
Recent studies have revealed significant chromosomal changes that take place during the long-
term culture of iPSCs as well as variations in the number of copies of certain genes and point
mutations, which could clearly be related with the reprogramming of somatic cells and result
in damage to the DNA [112-115].
The second hurdle that must be overcome is the high variability that exists between the
different cell lines in the context of differentiation into pancreatic lineages [16]. The epigenetic
and functional trials that should be performed in this respect are complicated by the fact that
iPSCs have a high epigenetic content [116]. The third obstacle has to do with the purification
of iPSC-derived β cells to prevent the transplantation of undifferentiated cells, which could
result in the formation of teratomas. Moreover, it is necessary to develop new reagents to make
direct differentiation of pancreatic progenitors into functional β cells more efficient and to
design highly specific surface markers for these cells so that a more precise fluorescence
analysis can be performed in order to isolate homogeneous populations of this kind of cell so
that their function can be rigorously controlled.
6. General regulatory and bioethical issues
Cell therapy, as one of the bedrocks of the advanced therapies —together with gene therapy
and tissue engineering—, requires a new legislative framework in order to guarantee that
patients can avail themselves of the products they need and provide governments with a robust
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protection, control and regulation mechanism. The existing framework regulating advanced
therapies will have to be adapted fast in order to keep pace with the proliferation of new
knowledge in this rapidly developing field. However, desirable that this may be, the pace of
legislative reform is unfortunately slow and inevitably lags behind the development of new
science.
The aspects to be regulated include mainly those related with controlling the development,
manufacturing and quality of release and stability testing programs; non-clinical aspects such
as promoting research on biodistribution, cell viability and proliferation levels and ratios, and
the persistence of in vivo function; clinical aspects such as dose-specific characteristics, risk
stratification; and aspects specifically connected to pharmacovigilance and traceability.
The guidelines for therapeutic products based on human cells must be drawn up by the drug
agencies of the different countries [117,118] both as regards the development of clinical and
preclinical trials and with respect to pharmacovigilance, taking in all cases a multidisciplinary
perspective.
For any product based on cells or on tissue, it should be made compulsory to verify that the
desired physiological functions are preserved after the preparation process, both in isolation
and in combination with other non-biological components, as many of these products will be
used with a metabolic purpose [119,120]. Nevertheless, many things remain to be learned about
the procedures that should be followed to guarantee the safety and efficacy of cell therapy
products, especially with respect to the biology of stem cells, their self-renewal and differen‐
tiation potential and, above all, the evaluation and prediction of potential risks.
Most cell therapy products are not controversial from a bioethical point of view. The exception
to this is therapy with human embryonic stem cells, which raises moral and bioethical
problems [121,122]. Such consideration refer to the donor's informed consent and to problems
associated with the harvesting of oocytes and the destruction of human embryos. In this regard,
the guidelines used by the different countries range from total prohibition to regulated
authorization. In general, there is an international consensus that the results obtained in stem
cell research should be applied to humans without prior bioethical scrutiny, with the under‐
standing that scientific research and the use of scientific knowledge must respect human rights
and the dignity of the individual in accordance with the Universal Declaration of Human
Rights and the Universal Declaration of the Human Genome [123].
The main advantage of induced pluripotent stem cells is that their use, unlike that of embryonic
stem cells, does not raise moral or bioethical issues as the scientific community, as well as
society at large, consider it a valid alternative for the generation of pluripotent stem cells
without the need to use human oocytes or embryos. Furthermore, these cells have shown
themselves to be functionally and molecularly similar to embryonic cells, but without their
bioethical problems, which means that their use in humans will not require an overly stringent
regulatory framework. The importance of this cannot be overstated as, in many instances, and
in some countries more than in others, legislation can hinder the development of science and,
consequently, the application of new knowledge and new therapeutic strategies.




iPSCs offer an unprecedented alternative for basic, clinical and applied biomedical research.
The most significant applications of these cells to the field of cell therapy are related to the
treatment of such organ-specific conditions as diabetes ―a typically metabolic disease―,
hepatic and cardiovascular diseases, immunological disorders and monogenic hereditary
conditions in general such as haemophilia.
However, many aspects remain to be unveiled about the safety of iPSCs and about their
reprogramming mechanisms, although no-one denies that this technology offers new, until-
recently-unimaginable possibilities for correcting alterations in a large number of conditions,
particularly in monogenic and metabolic diseases [124]. Also, some technical problems will
also have to be resolved such as finding a way to produce these cells using risk-free viral vector
transfection as well as safer alternative methods such as viral vector-mediated reprogramming.
Other more general, though no less important, issues that remain to be addressed include
optimal extrapolation to humans of the high levels of safety and expression obtained in animal
models and finding out whether it is adult mesenchymal stem cells or iPSCs that constitute
the best and most easily applicable alternative for the administration of combined cell therapy/
gene therapy.
For the reasons mentioned it is imperative not to create false expectations in patients suffering
from a disease that is amenable to advanced therapies, specifically cell therapy, as these
strategies are still in their “infancy”. In the longer term, once the challenges mentioned above
have been overcome, both cell and gene therapy will become plausible alternatives. Optimism
is in order, but fantasy is best avoided.
As far as haemophilia is concerned, the first article discussing the benefits of gene therapy for
the treatment of the disease was published a decade ago. At that time, experts in the field
anticipated that a cure for haemophilia would be found by the first decade of the 21st century
[125], a prediction that did not come true because of multiple problems related to biosafety.
Although many steps have been taken in the right direction with respect to gene therapy,
cellular reprogramming of iPSCs and the safety of transfer vectors, efforts must continue in
order to resolve problems related to immune response, insertional mutagenesis, efficacy and
expression time, the collateral (particularly hepatotoxic) damage caused by viral vectors and
the risk of teratoma and neoplasia derived from the application of certain cell types. Sight
should not be lost of the difficulties inherent in recruiting patients for clinical trials and in the
large-scale production of vectors and cell lines, needed to facilitate optimal and efficient
implementation in the clinical setting.
One of the first things that must be addressed when doing research into advanced therapies
is whether the expected benefits of such therapies will be able to offset the investment needed.
In the case of haemophilia, the answer is clearly in the affirmative as it is a chronic disease that
requires high-frequency life-long treatment, very costly in patients on prophylaxis, and which
poses a potential risk of infection by emerging pathogens. The second question is whether
advanced therapies are at all feasible. In this regard, haemophilia is considered an optimal
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candidate for such treatments for several reasons: it is a monogenic disease; the expression of
low levels of coagulation factor (1-5%) can result in a moderate phenotype; a large variety
target cells can be applied; there is no need to regulate factor expression, and a large amount
of animal models are available for experimentation. In this regard, application of strategies
that are less demanding in terms of efficacy, i.e. level of protein expression, but that afford
much greater safety, may be an alternative for this condition, taking into account that both
physicians and patients are highly sensitive to the special immunologic situation of the
haemophilic population and that viral infections (HIV/HCV) have had lethal consequences for
these individuals in the past [76].
As regards diabetes as a typically metabolic disease, advances in the understanding of its
physio- and etiopathology, together with the greater biotechnological possibilities available,
have made new alternatives possible as a result of the development of advanced therapies to
treat it. Transplantation of insulin-secreting cells or of islets obtained a from differentiation of
stem cells could hold some hope in the long term.
As  in  haemophilia,  in  diabetes  it  is  also  necessary  to  justify  the  investment  of  human
and  financial  resources  required  for  the  development  of  new  advanced  therapeutical
strategies,  taking  account  of  the  fact  that  patients  with  this  condition  also  benefit  from
an optimal  and efficient  treatment at  present.  The justification for  the said investment is
that  diabetes  gives rise  to vascular  and neurological  complications in the long term and
that  transplantation  of  Langerhans  islets  has  not  achieved  the  success  that  scientists
hoped for  because  of  the  dearth  of  donors  and the  high  rate  of  immune rejection  that
characterizes  diabetic  patients.
In  a  nutshell,  iPSCs  technology  has  the  potential  to  produce  an  about-face  in  the  way
we conceive cell  behavior as  iPSCs can be induced to form hormone-producing differen‐
tiated  cells.  In  this  regard,  several  authors  have  reported  on  the  generation  of  insulin-
producing pancreatic  cells  from iPSCs  from rhesus  monkey and murine  models  which,
after  transplantation,  are  capable  of  producing  insulin  in  vivo  in  response  to  glucose
stimulation.  Nonetheless,  some  general  issues  affecting  iPSCs  remain  to  be  resolved
before  these  cells  can be  used clinically  in  the  treatment  of  diabetes.  Prominent  among
these are optimizing the reprogramming process as  well  as  their  genetic  safety,  control‐
ling  the  high  differentiation  variability  of  the  different  pancreatic  lines  by  means  of
epigenetic  trials  and  enhancing  the  purification,  isolation  and  characterization  of
homogeneous populations of  iPSC-derived insulin-producing β cells.
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